On June 29, 2021, Element Biosciences, Inc. closed the transaction. The company has issued 13,426,279 series C preferred stock for gross proceeds of $275,999,989.5193 in the transaction. The transaction includes participation from other new investors, Janus Henderson Group plc, Logos Capital Management, LLC, Meritech Capital Partners, Morgan Stanley Institutional Fund, Inc. - Counterpoint Global Portfolio, a fund managed by Morgan Stanley Investment Management Company and T. Rowe Price Group, Inc., and existing investors, Fidelity Management & Research Company LLC, Foresite Capital Management, LLC, JS Capital Management, LLC, RA Capital Advisors LLC and VR Adviser, LLC.

The company has raised approximately $400,000,000 in funding till date.